SkinQR uses mesotherapeutic drug aimed at combating hyper-pigmentation, various age spots, as well as freckles. This unique mesotherapeutic anti-aging cocktail, which includes growth factors and peptides, is used to even out skin tone and color, as well as eliminate hyperpigmentation. The formula contains encapsulated Arbutin, Vitamin C and Licorice extract, which acts by aggressively blocking the conversion of L-DOPA to eumelanin and pheomelanin by inhibiting the enzyme tyrosinase. The tool regulates the production of melanin. It brightens the skin quite effectively and also prevents the appearance of hyperpigmentation. The tool is used in the recovery period after laser skin rejuvenation procedures, as well as chemical peels to prevent post-inflammatory hyperpigmentation. Works to brighten and effectively prevent further skin pigmentation, leaves skin smooth soft and radiant. Active ingredients lighten pigmentation and age spots by reducing melanin synthesis.
Conditions Treated:
Sun Damage
Sun Spots
Freckles
Uneven skin tone
The clarifying mesotherapeutic agent enables active synthesis of melanin, perfectly prevents the appearance of age and age spots in various areas of the skin, intensively fights with existing spots. Skin brightening administration methods are standard injection methods and dermapen. The treated area requires prior disinfection. The drug itself is introduced exclusively micro-papular. Moreover, the depth of administration is intradermal, dermal-epidermal. Before using the product directly, it is necessary to collect a standard medical history of the client and negotiate with him the desired effect of the procedure. The main ingredients of the cocktail preparation are:
oligopeptides-34 CG-TGP2,
growth factors,
oligopeptide-50,
vitamin C (it blocks the function of free radicals, strongly promotes collagen production, intensely inhibits the overproduction of melanin),
arbutin (perfectly protects the skin from various injuries caused by free radicals, intensively inhibits the production of melanin),
plant extracts (have a remarkable whitening property, as well as antioxidant property),
pentapeptide-13 CG-ASP.
6 ACTIVE INGREDIENTS - The effectiveness of the drug is due to its composition, which includes 6 active ingredients
3 BIOMIMETIC PEPTIDES:
Oligopeptide -34 (C9-T9P2): Increases the decrease in MITF (microphthalmia-associated transcription factor), which, in turn, reduces the production of melanogenic factors. Suppresses the transmission of melanosomes to keranocytes.
Pentapeptide-13 (C9-ASP): Lightens the skin by blocking the combination of α-Melanocyte-stimulating hormone with MC1R.
Oligopeptide -50 (C9-Glamerin): Suppresses factors of melanogenesis, tyrosinase, TRP-1 (Tryptophan amino acid) and TRP-2 (Tryptophan amino acid). Reduces and prevents the appearance of age spots and hyperpigmentation.
VITAMIN C - 3-0 Ethyl Ascorbic Acid:
Effect on collagen synthesis, suppression of free radicals and localized overproduction of melanin.
ARBUTIN - Protects the skin from damage caused by free radicals. Stops the formation of the pigment melanin, inhibiting the activity of tyrosinase.
VEGETABLE EXTRACT Licorice Root Extract: Provides a whitening and antioxidant effect. INDICATIONS SkinQR Brightening Program for skin lightening acts by reducing the synthesis of melanin, thereby reducing skin pigmentation, the number of age spots and freckles. Used for men and women who have age spots and hyperpigmentation of various origins (melasma, chloasma, ephelids). Application specifics are described below. Method: dermapen / mesotherapy Area of application: Face, neck, décolleté, back of the hands, as well as the inner surfaces of the shoulder and hips.
Contraindications:
acute and chronic diseases in the acute stage,
pregnancy,
diabetes,
lactation,
malignant tumors.
HOW DOES ANTI-PIGMENTATION PROGRAM ACTUALLY WORKS?
ANTI-PIGMENTATION MECHANISM:
CG-ASP blocks the connection of α-Melanocyte-stimulating hormone with MC1R: Reduces melanin synthesis and tyrosinase activity in skin melanocytes.
CG-TGP2 and CG-Glamerin cause a decrease in MITF (microphthalmia-associated transcription factor): Suppresses the transmission of melanosomes to keranocytes.
Regular therapy with DEPIGMENTATION PROGRAM:
Stage 1: once a week (during the first month)
Stage 2: once every two weeks (during the second month)
Stage 3: once a month (during the third month)
Stage 4: once every one to two months (over the next six months)
Intensive care:
Stage 1: twice a week (during the first month)
Stage 2: once a week (during the second month)
Stage 3: once every two weeks (during the third month)
Stage 4: once every one to two months (over the next six months)
Determining the most appropriate treatment depends on the condition of the skin.
Comments